| Revista: | Annals of hepatology |
| Base de datos: | PERIÓDICA |
| Número de sistema: | 000413439 |
| ISSN: | 1665-2681 |
| Autors: | García Compean, Diego1 González González, José A1 Lavalle González, Fernando J1 González Moreno, Emmanuel I1 Maldonado Garza, Héctor J1 Villarreal Pérez, Jesús Z1 |
| Institucions: | 1Universidad Autónoma de Nuevo León, Hospital Universitario Dr. José Eleuterio González, Monterrey, Nuevo León. México |
| Any: | 2015 |
| Període: | Nov-Dic |
| Volum: | 14 |
| Número: | 6 |
| Paginació: | 780-788 |
| País: | México |
| Idioma: | Inglés |
| Tipo de documento: | Artículo |
| Enfoque: | Analítico, descriptivo |
| Resumen en inglés | About 80% of patients with liver cirrhosis may have glucose metabolism disorders, 30% show overt diabetes mellitus (DM). Prospective studies have demonstrated that DM is associated with an increased risk of hepatic complications and death in patients with liver cirrhosis. DM might contribute to liver damage by promoting inflammation and fibrosis through an increase in mitochondrial oxidative stress mediated by adipokines. Based on the above mentioned the effective control of hyperglycemia may have a favorable impact on the evolution of these patients. However, only few therapeutic studies have evaluated the effectiveness and safety of antidiabetic drugs and the impact of the treatment of DM on morbidity and mortality in patients with liver cirrhosis. In addition, oral hypoglycemic agents and insulin may produce hypoglycemia and lactic acidosis, as most of these agents are metabolized by the liver. This review discusses the clinical implications of DM in patients with chronic liver disease. In addition the effectiveness and safety of old, but particularly the new antidiabetic drugs will be described based on pharmacokinetic studies and chronic administration to patients. Recent reports regarding the use of the SGLT2 inhibitors as well as the new incretin-based therapies such as injectable glucagon-like peptide-1 (GLP-1) receptor agonists and oral inhibitors of dipeptidylpeptidase-4 (DPP-4) will be discussed. The establishment of clear guidelines for the management of diabetes in patients with CLD is strongly required |
| Disciplines | Medicina |
| Paraules clau: | Endocrinología, Farmacología, Gastroenterología, Cirrosis hepática, Diabetes, Resistencia a la insulina, Hipoglucemiantes |
| Keyword: | Medicine, Endocrinology, Gastroenterology, Pharmacology, Liver cirrhosis, Diabetes, Insulin resistance, Hypoglycemic agents |
| Text complet: | Texto completo (Ver PDF) |
